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Abstract
Background Pharmacologic options for treatment of osteolytic diseases especially in children are limited. Although not 
licensed for use, denosumab, a fully humanized antibody to RANKL, is used in children with good effects. Among others, 
one possible indication are giant cell tumors and aneurysmatic bone cysts. However, there are reports of severe hypercalcemia 
during weeks to months after termination of denosumab, that are rarely seen in adults.
Methods We collected data of four patients, aged 6–17 years, who experienced severe hypercalcemia after completion of 
treatment with denosumab for unresectable giant cell tumors of bone or aneurysmal bone cysts and methods of their treat-
ment. The detailed case information were described.
Results One patient was treated with long-term, high-dose steroid therapy, leading to typical Cushing’s syndrome. Another 
patient was restarted on denosumab repeatedly due to relapses of hypercalcemia after every stop. Finally, in two patients, 
hypercalcemia ceased definitely after treatment with bisphosphonates. However, several applications were necessary to 
stabilize calcium levels.
Conclusions There is a considerable risk of hypercalcemia as an adverse effect after denosumab treatment in children. 
Therapeutic and, preferably, preventive strategies are needed. Bisphosphonates seem to be an option for both, but effective 
proceedings still remain to be established.
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Introduction
Treatment of osteolytic diseases is known to be difficult 
as pharmacological possibilities are limited, particularly 
in children. For several years now, denosumab, a fully 
humanized antibody to RANKL, is available for treatment 
of postmenopausal osteoporosis and skeletal related events 
caused by bone metastases of certain solid tumors in adults 
[1]. It is an effective and quite frequently used therapeutic 
option, also as an alternative to bisphosphonates because of 
its faster treatment effect. By binding to RANKL (“recep-
tor activator of NFkappaB-ligand”) with very high affin-
ity, denosumab strongly blocks its interaction with RANK 
and thereby inhibits the formation of osteoclasts as well as 
their differentiation and activation. As a consequence, bone 
resorption is inhibited, resulting in an increase in bone mass 
[1–4]. In contrast, bisphosphonates block osteoclast activity, 
but not their development [1, 4–6]. Because of their strong 
adherence to hydroxylapatit, they remain in the bones for 
many years [1, 4–6], raising concerns about long-term con-
sequences especially when used in children [7]. For deno-
sumab, effects seem to be more temporary [3], but severe 
hypercalcemia may develop once treatment is stopped owing 
to a rapid loss of newly acquired bone caused by rebound 
formation and to activity of osteoclasts [3, 8–10].
In children, there currently is no approved indication for 
denosumab; however, it is used as an individual strategy or 
in clinical trials for several indications, especially certain 
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forms of osteogenesis imperfecta [11–13]. Denosumab is 
also used in the treatment of multiostotic fibrous dysplasia, 
juvenile Paget, giant cell tumors, aneurysmatic bone cysts 
and others [4, 9, 14–19]. Moreover, two NCT trial studies 
for the use of denosumab in children with giant cell tumor 
of bone are on their way [20] or have recently completed 
data acquisition [21].
Giant cell tumors and aneurysmatic bone cysts are simi-
lar, though not identical, expansive bone lesions that may 
occur in any bone of the body, being most prevalent in 
femur, tibia, radius, and pelvis. Although benign, these 
tumors and cysts can be locally very aggressive in their 
osteolytic activity and may cause significant bone destruc-
tion with sequelae of pain, weakness, deformity and patho-
logical fractures [8]. Surgery is the treatment of choice 
for giant cell tumors; whereas, non-surgical options are 
used in the treatment of aneurysmal bone cysts [10, 22, 
23], because epimetaphyseal (complete) resection is often 
impossible [8, 10, 17]. Histologically, giant cell tumors 
consist of sheets of neoplastic ovoid mononuclear cells 
interspersed with osteoclast-like giant cells expressing 
RANKL. Recruitment of osteoclast-like giant cells is 
thought to be related to the expression of RANKL on some 
mononuclear (stromal) cells, which are the actual tumor 
cells. Therefore, the giant cells themselves are responsi-
ble for the aggressive osteolytic activity of the tumor [8, 
10]. By taking these pathophysiological conditions into 
account, denosumab was thought to be a good therapeutic 
opportunity for irresectable giant cell tumors. Several tri-
als confirmed its efficacy [8, 10, 19, 23], and denosumab 
has now been approved for treatment of giant cell tumors 
in adults in the USA [10]. Although these tumors are most 
frequent in young adulthood (3rd and 4th decade) [4, 17], 
they rarely occur in children and adolescents. There are 
several case reports of successful treatment with deno-
sumab as well as ongoing trials in this age group [4, 9, 
14, 16, 17, 19–21]. Independently of the indication for its 
use, the risk of hypocalcaemia immediately after start of 
treatment with denosumab caused by increased calcium 
sequestration in bone is well-known, and calcium and 
vitamin D supplementation for its prevention is generally 
recommended now [15]. In contrast, along with the above-
mentioned notions of reactively increased osteoclast activ-
ity after cessation of denosumab, most of the reports on 
children mention hypercalcaemic episodes [4, 9, 14, 15, 18, 
19], which are often difficult to treat. These sequelae have 
not yet been systematically addressed in a clinical study. 
Nevertheless, with the increased off-label-use in children 
and with the severe symptoms of hypercalcaemia in most 
reports, we think it is necessary to be concerned about this 
topic. By presenting the cases of four children (Table 1), 
we would like to discuss possible options for therapy 
and, more importantly, the prevention of post-denosumab 
hypercalcaemia.
Methods
Four children, aged 6–17 years, presented to our children’s 
hospital for severe hypercalcemia after treatment with deno-
sumab for unresectable giant cell tumors of bone and for 
aneurysmal bone cysts. Therapy with denosumab had been 
started between 09/2011 and 12/2014. In all patients, the 
same treatment regimen for denosumab with a dose of 60 mg 
on days 1, 8, 15, 28, and then once a month had initially been 
used. Data on their medical course and on methods used for 
treatment of hypercalcemia were collected for each patient 
and were described as case reports.
Table 1  Patient characteristics
ABC aneurysmatic bone cyst, GCT giant cell tumor, BP bisphosphonates
Patient age at diag-
nosis (y)













Time to relapse 
(d)
1 12 ABC 17 17 None 1 mon BP 14
2 12 GCT 14 14 Tumor resection 2 mon Long-term 
steroids
None
3 6 ABC 9 12 Embolisation 3 mon Recurrently 
denosumab
Not exactly known
4 13 GCT 14 and 7 17 and 10 Partial resection 
and stabilisa-





BP 14 and 10




In October 2014, an 11-year-old boy was diagnosed with a 
solid variant of aneurysmatic bone cyst in the left os sacrum 
(Fig. 1a1, a2). The tumor caused intermittent pain in the 
left hip and leg. Surgical treatment was difficult owing to 
the localisation and extension of the tumor; therefore, off-
label-use of denosumab was started in November 2014 
at a dose of 60 mg on days 1, 8, 15, 28, and then once a 
month. When MRI and CT controls showed ossification 
of the lesion (Fig. 1b), denosumab treatment was gradu-
ally tapered by extending the interval between the doses 
from 4 to 8 weeks. Denosumab treatment was stopped after 
16 months of treatment. Two and a half months (76 days) 
after the last injection of denosumab, the boy presented to a 
peripheral children’s hospital with dizziness, nausea, vomit-
ing, and abdominal and generalized pain. Laboratory find-
ings showed severe hypercalcaemia (3.95 mmol/L). The boy 
was treated with hydration, furosemide, and corticosteroids. 
Symptoms and laboratory values improved only slightly and 
worsened again after 1 week; therefore, the boy was referred 
to our university children’s clinic. Initial blood tests showed 
a calcium level of 3.77 mmol/L. Given that other causes 
could be excluded, the hypercalcaemia was interpreted as a 
consequence of rebound increase of osteoclast activity fol-
lowing the denosumab therapy. To stop osteoclast hyper-
activity, we decided to administer bisphosphonates. After 
one infusion of neridronate 2 mg/kg, calcium level returned 
to lower-normal values (2.21 mmol/L) within 1 day and 
remained low for the next several days. During the follow-
ing days all other medications (hyperhydration, furosemide, 
prednisolone) could be stopped. However, 2 weeks later, 
the boy was readmitted to our hospital with the previous 
symptoms of hypercalcaemia. Though tight ambulant cal-
cium controls had still shown normal values 2 days before, 
calcium had risen to 3.68 mmol/L again. A second dose 
of neridronate 2 mg/kg was given with the same effect as 
before (calcium: 2.33 mmol/L 2 days later) (Fig. 2a). After-
wards, tight calcium controls always showed normal results 
for the following 6 months and also a year later, and parents 
reported no recurrence of symptoms (Fig. 2a, b). The aneu-
rysmatic bone cyst remained stable and partially calcified. 
Patient 2
In December 2014 a giant cell tumor in lumbosacral spine 
(L5/S1) was found in a girl aged 11 years. She was treated 
with denosumab starting in December 2014 with the same 
dose regime as in patient 1 for 12 months. When the tumor 
had diminished in size sufficiently, it could be curreted and 
denosumab treatment was tapered with extending intervals 
from 1–2 months, ending December 2015. Approximately 
3 months after the last dose of denosumab, the girl started 
to vomit and experienced nausea and abdominal pain. When 
she presented to a primary children’s clinic, she had hyper-
calcaemia (maximal level: 3.93 mmol/L) and prerenal renal 
failure. As with patient 1, rebound bone resorption after stop-
ping denosumab therapy was found to be the only explana-
tion. After treatment with hydration and furosemide failed 
to be effective, a high dose of prednisolone was started and 
was successful to normalize hypercalcaemia and to restore 
renal function. Aiming to prevent recurrent hypercalcemia, 
prednisolone treatment was continued at a lowered dose. One 
half year later, the dose of prednisolone was still as high as 
0.25 mg/kg/d and had caused relevant Cushing syndrome with 
weight gain, striae, weakness, and slight arterial hypertension. 
Fig. 1  Diagnostic imaging of patient 1. a1, a2 Initial computer 
tomography scan. b magnetic resonance tomography after 11 months 
of denosumab treatment
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The girl was sent to our endocrinology department with a 
request for safely reducing the cortisone treatment. Dose was 
tapered very slowly combined with tight calcium controls. 
Dose reduction was tolerated well, and no hypercalcemia 
occurred. When cortisone therapy could be stopped (Decem-
ber 2016), Trab5b, a marker of osteoclast activity, showed 
a normal level of 19 U/L (normal range: 9–22 U/L). Three 
months later, calcium level was still normal. Nevertheless, 
symptoms of Cushing’s syndrome were still present. Also, 
there was no recurrence of the giant cell tumor.
Patient 3
In July 2011, a 6-year-old child of Russian origin pre-
sented with pain and reduced sensitivity in his left thigh. 
A core needle biopsy was used to diagnose an aneuris-
mal bone cyst with typical osteoclast-like giant cells and 
intense vascularisation. Curettage and filling with bone 
chips was considered dangerous owing to the risk of bleed-
ing; therefore, treatment with denosumab was chosen as 
the first-line treatment. Within 2 months after the start 
Fig. 2  Calcium levels of patient 1. a During acute phase of hypercalcemia. b During hypercalcemia and 3 month follow-up. Dotted lines: normal 
range of calcium; asterixes: bisphosphonate doses
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of denosumab in September 2011 (60 mg every 4 weeks 
with two additional doses on days 8 and 15), the boy was 
free of pain and a control-CT-scan showed increasing bone 
density at the margins of the lesion. Then, an additional 
embolisation was performed. Treatment with denosumab 
was continued for 1 year till September 2012. The boy’s 
family returned home to Russia. Three months after deno-
sumab was stopped, the boy was admitted to a hospital in 
Russia because of dizziness, vomiting, lack of appetite, 
and tiredness. Laboratory investigations showed hyper-
calcemia of 4.14 mmol/L and metabolic alkalosis. The 
Russian colleagues restarted denosumab applications with 
30 mg every third month for 10 months until September 
2013. However, once this treatment was stopped, the boy 
developed another phase of hypercalcemia and a further 
one, after the latter had again resolved by a third course 
of denosumab. In January 2016, the boy was under stable 
condition with no further hypercalcemic events, no pro-
gression of the aneurysmal bone cyst, and no complaints.
Patient 4
In the fourth patient, a giant cell tumor localised in Th2, 
complicated by pulmonary metastasis, was identified in 
November 2012 at the age of 13 years. Owing to osteode-
struction of Th2 and to compression of the spinal channel, 
the patient was treated with denosumab (same dose regime 
with 60 mg on days 1, 8, 15, 28, and then once a month) 
from December 2012 until January 2014. Dorsal decom-
pression and spondylodesis of thoracic vertebra 1–3 could 
then be performed, as well as diagnostic partial lung resec-
tion on the right side and further resection of the giant cell 
tumor. After eighteen months (in August 2016), recurrent 
problems occurred which requiring the correction of spon-
dylodesis of cervical vertebra 7 to thoracic vertebra 4. For 
further stabilisation, the boy was treated with denosumab 
again for 7 months (September 2016–April 2017). With the 
experience of patient 1’s hypercalcemia in mind, patient 4 
was given a dose of bisphosphonates (ibandronate) in the 
orthopaedic department immediately after stopping deno-
sumab with the hope of preventing hypercalcemia in April 
2017.
However, in July 2017, (i.e., approximately 3 months 
after the final denosumab injection) the boy, aged 17 years, 
presented to a peripheral clinic with symptoms including 
dizziness, weakness, and vomiting for several weeks. Labo-
ratory results showed hypercalcemia > 4 mmol/L, which had 
developed in spite of the precautional bisphosphonate treat-
ment, and did not respond to conventional therapy with furo-
semide and prednisolone. Moreover, the boy showed mild 
renal failure, nephrocalcinosis stage II, and elevated blood 
pressure. As a consequence, he was transferred to the inten-
sive care unit of our university children’s hospital, where 
bisphosphonates (neridronat 2 mg/kg) were applied again. 
Two days later, calcium returned to normal, and the boy 
wasdischarged. Unfortunately, the boy had to be readmitted 
14 days after the infusion of neridronate owing to recurrent 
dizziness and vomiting. Calcium was elevated again with 
3.90 mmol/L. After another dose of neridronat (2 mg/kg), 
calcium levels dropped, but only to 2.85 mmol/L. Keeping 
the high cumulative amount of bisphosphonates in mind, 
we gave neridronate again 10 days later, but reduced in dose 
(1 mg/kg). Finally the boy could be discharged then with at 
least high-normal calcium levels (2.59 mmol/L; Fig. 3). Cal-
cium levels remained in the normal range for the following 
2 months, but 3 months later computer tomography showed 
significant progression of the giant cell tumor as well as the 
pulmonary metastases, so denosumab was restarted (60 mg 
every 3  months). Meanwhile, with stabilisation of the 
lesions, the treatment is tapered again, but is still ongoing.
Fig. 3  Calcium levels of patient 
4. Dotted lines: normal range of 
calcium; asterixes: bisphospho-
nate doses
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Discussion
Few reports exist on hypercalcemia after treatment with 
denosumab, as seen in the four patients presented here. Ini-
tially, Gossai et al. [14] as well as Setsu et al. [4] described 
hypercalcemia in children treated with denosumab for giant 
cell tumors. Uday et al. [18] added case reports of two 
more adolescents and a 40-year-old man. Grasemann et al. 
[13] found this side effect in a child with juvenile Paget, 
and Boyce et al. [9] in a boy with severe fibrous dyspla-
sia both treated with denosumab. Recently, Kurucu et al. 
[19] and Dürr et al. [24] reported reactive hypercalcemia 
in several denosumab-treated children and adolescents with 
aneurysmatic bone cysts, the phenomenon clearly must be 
related to the treatment.
To explain these observations, the following pathopyh-
siologic hypothesis was proposed. According to the mecha-
nostat model [25, 26], the body has a certain setpoint for the 
adequate quantity of bone for its muscle mass and physi-
ological needs. The newly acquired bone during denosumab 
treatment is not limited to local lesions, such as aneurys-
matic cysts or fibrous deformities. Because of the lack of 
osteoclast activity, bone mass cannot be adapted to the 
physiologic needs and is judged as being excessive. With 
cessation of denosumab treatment, the inhibitory effect on 
osteoclasts stops, resulting in a reactive exaggerated activity 
of these cells [4, 14]. Kurucu et al. [19] could prove these 
theoretic approaches to be true by showing not only sup-
pressed parathormone but also high deoxypyridinoline levels 
indicating a rebound increase in osteoclastic activity. The 
resulting surplus of bone resorption allows a high amount 
of calcium ions to be set free, leading to hypercalcaemia. In 
adults, a transient rise of bone turnover markers after cessa-
tion of denosumab treatment has been reported several times 
[8–10, 26, 27] and can be regarded as a proof of this theory. 
In older patients treated mainly (but of course, not exclu-
sively) for osteoporosis, these observations lead to concerns 
that the effect of gaining bone mass by denosumab might 
soon be lost afterwards [8–10]; however, there are only few 
case reports of symptomatic hypercalcemia in adults that 
stopped treatment [5, 18]. On one hand, this might be due 
to the lack of reports on follow-up, which also do not exist 
for many case presentations in children; on the other hand, 
a higher incidence in children might be explained by a gen-
erally more active turnover and by acquisition of bone in 
growing children and adolescents [9].
This phenomenon is additionally supported by the obser-
vation of increases in calcium and bone resorption markers 
in children with osteogenesis imperfecta at the end of the 
interval before their next dose of denosumab [28]. Their 
lower rate of hypercalcemia might be due to their gener-
alized low bone mass and at least in part, that they were 
pretreated with bisphosphonates. In giant cell tumors or in 
aneurysmatic bone cysts instead, there is only a local defi-
ciency of bone. Moreover, in the studies of patients treated 
for osteogenesis imperfecta, doses of denosumab were 
much lower (1 mg/kg/dose) [11, 28] than in the reports on 
giant cell tumors and aneurysmatic bone cysts in children. 
In them, mainly the standard dosage for adults adapted 
from a phase 2 clinical trial in adults [29] were used. As a 
result, the four patients described in our case report received 
approximately 2-3 mg/kg/dose (exact data cannot be given 
as initial weight was unfortunately not available). Neverthe-
less, in the already mentioned children with juvenile Paget 
[15] and fibrous dysplasia [9], symptomatic hypercalcemia 
occurred in spite of lower doses (1.0 mg/kg, then increased 
to 1.75 mg/kg and 0.5 mg/kg). This implies that while dose 
regimes might play a role for the individual risk of hyper-
calcemia, other, thus far unknown, factors must coexist. The 
impossibility of predicting individual risk for hypercalcemia 
after denosumab treatment and the extent of hypercalcemia 
is shown impressively by patient 4, in whom no hypercalce-
mia was seen after the first, but after the second treatment. 
A subclinical hypercalcemia after the first use, of course, 
cannot be excluded, even more as nephrocalcinosis stage II 
was already present at onset of the adverse event after the 
second phase.
Hypercalcemia must certainly be considered a serious 
adverse event, as all of the children reported with hyper-
calcemia after cessation of denosumab showed quite severe 
symptoms, such as fatigue, nausea, vomiting, constipation, 
abdominal pain, weight loss, polyuria, dehydration, renal 
failure, and sinusbradycardia (1 report), which often devel-
oped within a few days [4, 9, 14, 15]. Fortunately, thus far 
they did not, but could, in part, become life-threatening.
Therefore, to underscore demands already raised by Uday 
et al. [18], it seems to be necessary to develop safety con-
cepts for weight-adjusted dosing, frequency and duration 
of therapeutic use of denosumab in children. Additionally, 
monitoring calcium levels at the end of treatment should be 
mandatory.
Given the current state of knowledge, neither the risk nor 
the exact timing of onset of hypercalcemia can be antici-
pated for a single individual. There are no data on real fre-
quency of these sequelae. So far, there are only two case 
series reports of children with and without hypercalcemia 
after treatment [19, 24]. An incidence of 22, respectively, 
20% could be calculated, but, of course, the sample size is 
too small to generalize these data. The interval between the 
last dose of denosumab and hypercalcemia was between 2.5 
and 3 months in all of the patients reported here, regard-
less if treatment had been tapered to 2-monthly intervals 
(patient 2 and 3) or continued monthly till the end (patient 
3 and 4). Others [4, 14, 15, 18, 19] reported an interval of 
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7 weeks to 5 months, although it has to be added that the 
child in which hypercalcemia occurred after 7 weeks was 
still on substitution with calcium because of initial hypoc-
alcemia after denosumab injections. The mean half-life of 
denosumab is of about 29 days (range 25–35 days) [30], but 
it may be prolonged in individuals with accumulated doses 
[18]. As a result, duration of denosumab treatment might 
also be relevant for the timing of onset of hypercalcemia. 
Our patients were treated between 7 and 16 months. The 
treatments of other patients lasted between 14 and 24 months 
[4, 14, 18, 19]. From these few reports, we cannot conclude 
with certainty that a correlation between duration of therapy 
and time to onset of hypercalcemia exists. An additional 
influencing factor, among others, might also be the indi-
vidual vitamin D level [18].
Most important, however, is the urgent need to evolve 
effective strategies to manage these hypercalcaemic epi-
sodes. In the patients reported here and by others, “con-
ventional” methods like hydration combined with diuretics 
and short-time corticosteroids showed no or only transient 
effects. To our knowledge, there is no evidence that high-
dose steroids for a prolonged interval, as in patient 2, would 
really be effective to surpass the interval till the reactive 
bone resorption would probably have declined. Short- and 
long-time sequelae of Cushing syndrome should be kept in 
mind. Restarting denosumab also appears not to be the solu-
tion (e.g., patient 3). Instead, bisphosphonates (single dose 
or repeated), which were finally used in almost all reported 
patients [4, 5, 9, 14, 15, 18], led to normalization of calcium.
Additionally, prevention of hypercalcemia in denosumab-
treated children should be of higher interest. Thus far, there 
are no reports in the literature concerning this topic. In our 
opinion, bisphosphonates might be helpful. Although deno-
sumab has actually been used in several cases in children 
when bisphosphonates failed to achieve the expected effect, 
the combination with bisphosphonates is worth considering: 
one of the modes of action of bisphosphonates is their long-
lasting adherence to bone matrix and by this preventing bone 
resorption. Therefore, bisphosphonates also could reduce 
the activity of the reactively formed new osteoclasts after 
cessation of denosumab therapy and consequently could 
avoid severe hypercalcemia and its symptoms. This was the 
hypothesis we used—to our knowledge for the first time—to 
give a dose of bisphosphonates to prevent hypercalcemia 
in patient 4. Unfortunately, our attempt was not successful, 
but in our opinion, it is nevertheless worth considering fur-
ther. Maybe the time point and/or frequency or even dosage 
of bisphosphonates require adjustment. Urgency of further 
research on this topic is impressively shown by patient 4.
For future patients on denosumab, pretreatment with bis-
phosphonates might be a possible option for prevention of 
hypercalcemia. But as some of the children in whom hyper-
calcaemia was observed had formerly been treated with 
bisphosphonates, also the time interval to the start and end 
of denosumab seems to matter. As well pretreatment with 
bisphosphonates combined with a dose soon after stopping 
denosumab and/or another one about 1 month later could be 
a strategy worth trying.
In conclusion, although denosumab is not yet licensed in 
children and adolescents, more and more studies revealed it 
is efficacious not only in giant cell tumors and aneurysmatic 
bone cysts but also in several other osteolytic diseases. How-
ever, and different from adults, severe hypercalcaemia after 
the end of the treatment seems to be rather frequent, due to 
the generally higher bone turnover in growing children. In 
our opinion, it is crucial to think about strategies of treat-
ment and even more, prevention. Bisphosphonates could be 
an option for both. To find the right timing and dose regi-
mens for preventive use, more studies are needed.
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